Luspatercept-aamt (Reblozyl®)

Reblozyl (luspatercept‑aamt) is covered only for adults (≥18 years) with beta thalassemia who require regular RBC transfusions (transfusion‑dependent); non‑transfusion‑dependent patients and non‑FDA indications are excluded. Initial approval requires hematologist prescribing/consultation, documented transfusion dependence and age, dosing ≤1.25 mg/kg SC every ≥3 weeks with a 4‑month initial approval and 12‑month renewals contingent on documented clinically meaningful reduction in transfusion burden.

"Reblozyl is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions."

Sign up to see full coverage criteria, indications, and limitations.